HC Wainwright Predicts OTCMKTS:MDNAF Q1 Earnings

Medicenna Therapeutics Corp. (OTCMKTS:MDNAF) – Research analysts at HC Wainwright issued their Q1 2028 earnings per share (EPS) estimates for Medicenna Therapeutics in a report issued on Thursday, August 20th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.04) for the quarter. The consensus estimate for Medicenna Therapeutics’ current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Medicenna Therapeutics’ Q2 2028 earnings at ($0.04) EPS, Q3 2028 earnings at ($0.04) EPS, Q4 2028 earnings at ($0.04) EPS and FY2031 earnings at $0.26 EPS.

Medicenna Therapeutics (OTCMKTS:MDNAF) last released its earnings results on Thursday, June 25th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05).

Medicenna Therapeutics Stock Down 1.0%

Medicenna Therapeutics stock opened at $0.30 on Friday. The stock’s 50 day moving average is $0.27 and its 200 day moving average is $0.41. Medicenna Therapeutics has a twelve month low of $0.23 and a twelve month high of $1.43. The company has a market capitalization of $27.41 million, a P/E ratio of -1.86 and a beta of 1.78.

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.